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Abstract
Background: Obesity is one of the principal causative factors involved in the development of metabolic syndrome.
AMP-activated protein kinase (AMPK) is an energy sensor that regulates cellular metabolism. The role of AMP-activated
protein kinase in adipocyte differentiation is not completely understood, therefore, we examined the effect of 5-
aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR), a pharmacological activator of AMP-activated protein
kinase (AMPK) on adipocyte differentiation in 3T3L1 cells and in a mouse Diet induced obesity (DIO) model.
Methods: To examine the effect of AICAR on adipocyte differentiation in 3T3L1 cells and in a mouse Diet induced
obesity (DIO) model, 3T3L1 cells were differentiatied in the presence or absence of different concentration of AICAR
and neutral lipid content and expression of various adipocyte-specific transcription factors were examined. In vivo study,
treated and untreated mice with AICAR (0.1–0.5 mg/g body weight) were fed high-fat diet (60% kcal% fat) to induce DIO
and several parameters were studied.
Results: AICAR blocked adipogenic conversion in 3T3L1 cells along with significant decrease in the neutral lipid content
by downregulating several adipocyte-specific transcription factors including peroxisome proliferators-activated receptor
γ (PPARγ), C/EBPα and ADD1/SREBP1, which are critical for adipogenesis in vitro. Moreover, intraperitoneal
administration of AICAR (0.5 mg g/body weight) to mice fed with high-fat diet (60% kcal% fat) to induce DIO, significantly
blocked the body weight gain and total content of epididymal fat in these mice over a period of 6 weeks. AICAR
treatment also restored normal adipokine levels and resulted in significant improvement in glucose tolerance and insulin
sensitivity. The reduction in adipose tissue content in AICAR treated DIO mice was due to reduction in lipid
accumulation in the pre-existing adipocytes. However, no change was observed in the expression of PPARγ, C/EBPα and
ADD1/SREBP1 transcription factors in vivo though PGC1α expression was significantly induced.
Conclusion: This study suggests that AICAR inhibits adipocyte differentiation via downregulation of expression of
adipogenic factors in vitro and reduces adipose tissue content in DIO mice by activating expression of PGC1α without
inhibiting adipocyte-specific transcription factors in DIO mice.
Published: 10 August 2006
Nutrition & Metabolism 2006, 3:31 doi:10.1186/1743-7075-3-31
Received: 05 May 2006
Accepted: 10 August 2006
This article is available from: http://www.nutritionandmetabolism.com/content/3/1/31
© 2006 Giri et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Nutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
Page 2 of 20
(page number not for citation purposes)
Background
The intake of calorie-rich fast food and sedentary lifestyles
of developed countries has sharply increased the inci-
dence of obesity. Obesity is not only a serious health and
economic burden, but also predisposes a person to a vari-
ety of metabolic diseases (i.e., the coexistence of several
risk factors for atherosclerosis, hyperglycemia, dyslipi-
demia, and hypertension), where the mechanistic role of
obesity is yet to be fully elucidated. Obesity is simply the
consequence of an imbalance between energy intake and
expenditure by the body from a metabolic point of view.
The main sites of energy utilization, skeletal muscle and
adipose tissue play significant roles in the regulation of
energy homeostasis. Skeletal muscles are one of the major
organs responsible for insulin-mediated glucose disposal,
and maintenance of glucose homeostasis of the body.
Adipose tissue serves as an energy storage depot to main-
tain lipid homeostasis, thereby promoting the survival
ability of the human body [1]. Obesity occurs when the
adipose tissue is overloaded with high-energy nutrients
without subsequent expenditure.
Because adipocytes play a critical role in energy balance,
understanding the molecular mechanisms of adipocyte
differentiation may provide clues for developing strategies
for the prevention and treatment of obesity. The mecha-
nisms of adipocyte differentiation have been extensively
studied in preadipocyte culture systems. Characterization
of the regulatory regions of adipose-specific genes has led
to the identification of key transcription factors in the
complex transcriptional cascade that occurs during adi-
pocyte differentiation [2]; these factors include peroxi-
some proliferator-activated receptor γ (PPARγ) [3],
CCAAT/enhancer binding protein (C/EBP) [4,5], adipocy-
tedifferentiation and determination factor 1(ADD1), and
sterolregulatory element binding protein 1c (SREBP1c)
[2,6-8].
In addition to functioning as the principal energy storage
depot, adipose tissue secretes hormones (adipokines) that
contribute to energy homeostasis [9]. One such hormone,
leptin, acts chiefly through the brain to regulate food
intake and energy expenditure. Other adipokines, includ-
ing tumor necrosis factor-α (TNFα), adiponectin, adipsin,
and interleukin-6 (IL-6) can also regulate the inflamma-
tory response [10-13]. The list of cytokines identified in
white adipose tissue (WAT) is increasing, suggesting that
obesity also results in a chronic, low level of inflamma-
tion through production of these proteins [11-15]. This
inflammatory state may contribute to major obesity asso-
ciated complications, including type 2 diabetes, cardio-
vascular disease, and the metabolic syndrome. Also,
adipose TNFα expression is increased in obesity and has
been shown to contribute towards insulin resistance [11].
The AMP-activated protein kinase (AMPK) is an evolu-
tionarily conserved sensor of cellular energy status, and
plays a critical role in systemic energy balance in response
to metabolic stress [16-18]. AMPK is a serine/threonine
protein kinase and a member of the Snf1/AMPK protein
kinase family [16-18]. It is a αβγ heterotrimeric protein,
consisting of a α catalytic subunit, a β subunit important
both for enzyme activity and for targeting, and a γ regula-
tory subunit, which binds the allosteric activator, AMP.
The activity of AMPK absolutely requires phosphorylation
of the α subunit on Thr-172 in its activation loop by one
or more upstream kinases (AMPKK) [16]. AMPK inte-
grates nutritional and hormonal signals in peripheral tis-
sues with the hypothalamus and also mediates adipokine
effects (leptin, adiponectin, and possibly resistin) in regu-
lating food intake, body weight and glucose and lipid
homeostasis. Recently, CaMKKs and LKB have been iden-
tified as its upstream kinase, AMPKK [19-21]. 5-Aminoim-
idazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) is
a known activator of AMPK and has been used as an exper-
imental tool to activate AMPK in vitro and in vivo. It has
been shown that chronic administration of AICAR in rats
resulted in marked changes in skeletal muscle that
included increases in glycogen stores and GLUT4, and
increased activity of hexokinase and mitochondria oxida-
tive enzymes [22-24]. Administration of AICAR also led to
an increase in maximal insulin-stimulated glucose trans-
port and GLUT4 translocation [25]. Altogether it is con-
ceivable that repetitive activation of AMPK may be part of
the mechanism leading to improved insulin action after
exercise.
In the present study, we examined the effect of AICAR on
adipocyte differentiation using an in vitro model, i.e.
3T3L1 cell line, and an in vivo diet induced obesity mouse
model.
Methods
Reagents
AICAR was purchased from Toronto Chemicals. Antibod-
ies against phosphospecific as well as nonphospho-
AMPKα and ACC were from Cell Signaling (Beverly, MA).
Antibodies against AMPK α1 and α2 were from Abcam
(Cambridge, MA). Antibodies against C/EBPα, C/EBPβ,
SREBP1, PPARγ, β actin and proteinA/G plus agarose were
from Santa Cruz Biotechnology (Santa Cruz, CA).
[3H]Thymidine was from PerkinElmer Life Sciences (Bos-
ton, MA). 5-iodotubercidin was purchased from Calbio-
chem (San Diego, CA).
3T3-L1 cell culture and differentiation
3T3-L1 preadipocytes were cultured in Dulbecco's modi-
fied Eagle's medium (DMEM) containing 10 % (v/v) NBS.
AICAR was dissolved in DMSO for cell culture studies (0.5
M, stock). On day 0 (2 day after 3T3-L1 preadipocytesNutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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reached confluence), cells were induced to differentiate by
insulin (1.7 μmol/L), IBMX (0.5 mmol/L), and DEX (1
μmol/L). On day 3 and every other 3rd day thereafter, fresh
regular medium was substituted until day 9 [19]. Differ-
entiation was monitored by morphological assessment
and Oil red O staining [20]. For Oil red O staining, cells
were washed twice with PBS, fixed in 3.7 % formaldehyde
for 1 h, and stained for 30 min with 0.2 % (w/v) oil red O
solution in 60 % (v/v) isopropanol. Cells were then
washed several times with water, and excess water was
evaporated by placing the stained cultures at approxi-
mately 32°C. In order to determine the extent of adipose
conversion, 0.2 ml of isopropanol was added to the
stained culture dish. The extracted dye was immediately
removed by gentle pipetting and its optical density was
monitored spectrophotometrically at 510 nm. For cell
proliferation, 3T3L1 cell were kept in differentiating
media in the presence of AICAR/iodotubercidin (0.5 mM/
0.1 μM) for three days. [3H] thymidine (1 μCi/well) was
added at the end of the treatment for 6 h and mean incor-
poration of thymidine in DNA was measured by a 1450
Microbeta Wallac Trilux Liquid Scintillation Counter (Per-
kin-Elmer Life Sciences) as described before [26].
Mice
Male C57BL/6 mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). Mice were fed a high-fat diet
(60% kcal% fat) (Research Diets, New Brunswick, NJ) ad
libitum for 6 weeks. At 1, 2, 4 and 6 weeks, animals were
sacrificed and various tissues harvested, weighed, and
processed for subsequent analysis. All procedures were
performed in accordance with the experimental guide-
lines for animal care and use at the Medical University of
South Carolina (Charleston, SC, USA).
Administration of AICAR
To study the effect of AICAR, five groups of mice were allo-
cated into group 1: mice fed with standard diet (STD);
group 2: STD mice treated with AICAR (0.5 mg/g bw);
group 3: mice fed high fat diet (DIO); group 4: DIO mice
treated with AICAR (0.1 mg/g bw); group 5: DIO mice
treated with AICAR (0.5 mg/g bw). The mice were treated
with AICAR (0.1 or 0.5 mg/g body weight, dissolved in
PBS, i.p. injection volume of 200 μl/mouse) three times a
week for 6 weeks (Monday, Wednesday and Friday). Mice
in the control group received 200 μl of PBS.
Histology and cell-size measurement
Freshly isolated epididymal white adipose tissue from
treated and untreated mice was fixed in 10% formalin and
embedded in paraffin. Sections (8 μm) were stained with
hematoxylin and eosin, and cell morphology and size
were analyzed.
RNA extraction, Northern blot analysis, and real-time PCR
After extraction of total RNA from white adipose tissue
using of TRIzol (Invitrogen) as per the manufacturer's
protocol, total RNA (5 μg) was used to prepare cDNA
using iScript cDNA Synthesis Kit (BioRad Laboratories).
Real-time PCR was performed as described previously uti-
lizing Bio-Rad iCycler (iCycler iQ Multi-Color Real-Time
PCR Detection System) using iQ SYBR Green Supermix
reagent as per the instructions from BioRad Laboratories.
The primer sets for use were designed (Oligoperfect
Designer, Invitrogen) and synthesized from Integrated
DNA Technologies. The primer sequences for PPARγ,
SREBP1, C/EBPα, aP2, Adipsin and 18S taken from Le Lay
et al [27]. Primer sequences are follows: DGAT1 for, 5'-
TTCCGCCTCTGGGCATT-3'; rev, 5'-AGAATCG-
GCCCACAATCCA-3'; GPAT for, 5'-ATTGACACCTGCT-
GCTTTTGA-3'; rev, 5'-CCTACCCACTACAACAGAG-3'.
Thermal cycling conditions were as follows: activation of
DNA polymerase at 95°C for 10 min, followed by 40
cycles of amplification at 95°C for 30 sec and at 58.3°C
for 30 sec. The normalized expression of target gene with
respect to 18S was computed for all samples by using the
Microsoft Excel data spreadsheet.
AMPKα1 activity
AMPKα1 activity was assayed in isolated epididymal
white adipose tissue from different groups using anti-
AMPKα1 antibody for immunoprecipitation. For this, iso-
lated epididymal white adipose tissues were homoge-
nized in lysis buffer (50 mM Tris-HCl, pH 7.4, containing
50 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 10% glycerol,
1% triton X-100 and protease inhibitor mixture). Approx-
imately 200 μg of tissue homogenate was incubated with
anti-AMPKα1 antibody for 2 hr, then 30 μl of protein A/
G plus agarose was added and incubated for an additional
1 hr at 4°C. The immune complexes were washed twice in
lysis buffer and twice in kinase buffer (62.5 mM HEPES,
pH 7.0, 62.5 mM NaCl, 62.5 mM NaF, 6.25 mM sodium
pyrophosphate, 1.25 mM EDTA, 1.25 mM EGTA, and 1
mM dithiothreitol), incubated at 30°C in 30 μl of kinase
assay buffer containing 200 μM AMP, ATP mixture (200
μM ATP and 1.5 μCi of [γ-32P]ATP), with or without 250
μM SAMS peptide (HMRSAMSGLHLVKRR) for 20 min.
The reaction was terminated by spotting the reaction mix-
ture on phosphocellulose paper (P81), and the paper was
extensively washed with 150 mM phosphoric acid. The
radioactivity was measured with a scintillation counter as
described before [28].
Tissue lipid content and fatty acid composition
Lipids were extracted by the Folch method in a mixture of
2:1 chloroform/methanol (vol/vol). The extract was
washed with 0.2 volumes of saline (NaCl 0.9%) and cen-
trifuged at 2,000 rpm for 10 min. The organic phase was
recovered and serum triglycerides, cholesterol and freeNutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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fatty acids (FFAs) were analyzed using HPTLC as described
earlier [29]. Fatty acid composition of adipose tissue was
determined using GC17A and capillary column as
described [30].
Metabolic measurements
Blood glucose was measured with a glucometer
(AccuChek; Roche Diagnostics, Indianapolis, IN). Serum
adiponectin and leptin concentrations were determined
using a mouse adiponectin and mouse leptin enzyme-
linked immunosorbent assay kits (BioVendor Laboratory
Medicine, Inc.), respectively.
Glucose and insulin tolerance tests
A glucose tolerance test was performed on mice fasted for
12 h. Blood glucose levels were determined at 0, 15, 30,
60, and 120 min after an intraperitoneal injection of glu-
cose (2 g/kg body wt). For the insulin tolerance test, ani-
mals fasted for 5 h were injected intraperitoneally with 0.5
units insulin/kg body wt (sigma) and glucose levels were
measured at 0, 15, 30, 60, and 120 min postinjection.
Statistical analysis
Results shown represent means ± SD. Statistical analysis
was performed by ANOVA by the Student-Neumann-
Keuls test using GraphPad InStat software (San Diego,
CA).
Results
AICAR inhibits differentiation of preadipocytes
We investigated the effect of AICAR on the induction of
terminal differentiation markers at end of the differentia-
tion period (day 9). Oil Red O staining showed that
untreated differentiated cells had many lipid droplets
indicating lipid accumulation. However, lipid accumula-
tion was inhibited by AICAR treatment in a dose depend-
ent manner (Fig. 1a). This observation was further
supported with the quantitative analysis of neutral lipid
content by measuring the absorbance at 510 nM (Fig. 1b).
Untreated and AICAR treated (0.1 mM) differentiated
3T3L1 cells showed higher levels of lipid staining with the
Oil Red O dye, which was significantly reduced by higher
doses of AICAR (0.25–1.0 mM) treatment (Fig. 1b).
To examine further the effect of AICAR on cell prolifera-
tion, undifferentiated 3T3L1 cells were treated with
increasing concentrations of AICAR (0.1–1.0 mM) in pro-
liferative media for 3 days and cell proliferation was
examined using [H3] thymidine uptake. AICAR at low
concentrations (0.1 and 0.25 mM) did not have any effect
on 3T3L1 cell proliferation but at higher concentrations
(0.5–1 mM) it completely blocked cell proliferation (Fig.
2).
AICAR inhibits key adipogenic transcription factors and 
markers
Adipogenesis is a highly regulated process requiring coor-
dinated expression and activation of key transcription fac-
tors which include CCAAT/enhancer binding proteins (C/
EBPs), peroxisome proliferators activated receptor gamma
(PPARγ), and sterol regulatory element-binding proteins
(SREBPs). To identify the molecular mechanism for the
inhibition of adipocyte differentiation by AICAR treat-
ment, the protein expression of key transcriptional factors
for adipocyte differentiation was examined (Fig. 3a). The
levels of C/EBPα protein expression in 3T3L1 during dif-
ferentiation increased at day 6 and 9, which was inhibited
by AICAR treatment in a dose dependent manner (Fig.
3a). However, the expression of C/EBPβ levels was unaf-
fected by AICAR treatment. The expression of PPARγ and
SREBP-1 was also significantly inhibited by AICAR treat-
ment at 0.5 to 1 mM concentration (Fig. 3a). To support
further these observations, the mRNA levels of these tran-
scription factors were examined by quantitative analysis
using real time PCR. As depicted in figure 3b, the mRNA
expression of C/EBPα, PPARγ and SREBP-1 was signifi-
cantly increased with the progression of adipocyte differ-
entiation. AICAR treatment at the concentration of 0.5
mM significantly blocked the expression of these key adi-
pogenic transcription factors (Fig. 3b), further confirming
that AICAR inhibits adipocyte differentiation by inhibit-
ing expression of C/EBPα, PPARγ and SREBP-1. Modula-
tion of the expression of other adipocyte-specific markers
including Pref-1, aP2 and adipsin, further supported these
observations (Fig. 3b). Pref-1 is a marker for preadi-
pocytes and inhibits adipocyte differentiation [31],
whereas, aP2 and adipsin are markers for differentiated
adipocytes [32,33]. The expression of Pref-1 was signifi-
cantly reduced with increase in adipocyte differentiation;
however, its expression was restored with AICAR treat-
ment (Fig. 3b). AICAR treatment also reduced the expres-
sion of aP2 and adipsin mRNA as compared to untreated
differentiated cells (Fig. 3). Taken together, AICAR inhib-
ited the expression of key transcription factors (C/EBPα,
PPARγ and SREBP-1), adipocyte specific markers, thereby
blocking the adipocyte differentiation.
Adenosine kinase inhibitor inhibits AICAR mediated 
inhibition of 3T3L1 differentiation
We were further interested in examining the role of ZMP
(a phosphorylated form of AICAR, which mimics AMP to
activate AMPK) in the regulation of AICAR mediated inhi-
bition of adipocyte differentiation. 3T3L1 cells were
treated with AICAR (0.5 mM) on different days (from 0, 3
and 6th day) in the presence or absence of iodotubercidin.
Iodotubercidin is an inhibitor of adenosine kinase, and
inhibits the conversion of AICAR to its activated form
ZMP inside the cell, and thus inhibits activation of AMPK
by AICAR [28,34]. Treatment with AICAR at any stage onNutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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either day 0 (proliferation phase), day 3 (differentiation
phase) or day 6 (late differentiation phase), significantly
blocked the accumulation of neutral lipid content as evi-
dent from Oil Red staining (Fig. 4a). Addition of iodotu-
bercidin together with AICAR at different stages (day 0, 3rd
or 6th) completely abolished the AICAR mediated inhibi-
tion of neutral lipid content accumulation (Fig. 4a), while
iodotubercidin treatment alone had no effect on adi-
pocyte differentiation. These results were further con-
firmed by examining for total lipid staining where
differentiated 3T3L1 cells have high levels of lipids, which
was completely abolished by AICAR treatment (Fig. 4b).
Addition of iodotubercidin significantly reversed AICAR
mediated inhibition in total lipid content (Fig. 4b). More-
over, iodotubercidin also reversed the AICAR induced
inhibition of cell proliferation in 3T3L1 cells as well as the
expression of SREBP1 and PPARg  (Fig. 4c, 4d), further
suggesting the involvement of ZMP in AICAR mediated
inhibition of adipocyte differentiation of 3T3L1.
Since ZMP is known to mimic AMP and activates AMPK,
the effect of AICAR on the phosphorylation status of
AMPK and ACC (acetyl CoA carboxylase) at various time
points was examined. As shown in figure 5a, the adipocyte
differentiation progressed with time; the phosphorylation
status of ACC and AMPK also increased, suggesting that
AICAR inhibits 3T3L1 adipocyte differentiation in a dose dependent manner Figure 1
AICAR inhibits 3T3L1 adipocyte differentiation in a dose dependent manner. The differentiating 3T3-L1 cells were 
treated with AICAR at various concentrations for 9 days (from day 0 to day 9). Intracellular lipid was stained with Oil Red O 
(a). To determine the extent of adipose conversion, 0.2 ml of isopropanol was added to the 12 well plates. The extracted dye 
was immediately removed and its optical density was monitored spectrophotometrically at 510 nm (b). Results are the mean ± 
SD of three determinations. $, p < 0.001 as compared with untreated cells; NS, not significant; ***, p < 0.001 as compared with 
untreated differentiated sample.Nutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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activation of AMPK occurs during adipocyte differentia-
tion. Treatment with AICAR further significantly increased
the phospho-status of ACC and AMPK in a dose depend-
ent manner, suggesting that AICAR induce the activation
of AMPK (Fig. 5).
To investigate whether the activation of AMPK is impor-
tant or not for adipocyte differentiation, cells were treated
with iodotubercidin together with AICAR for 9 days.
Chronic treatment with AICAR reduced the levels of phos-
pho-status of ACC, which was restored by iodotubercidin
treatment (Fig. 5b).
AICAR differentially regulates body weight in Diet induced 
obesity (DIO)
To assess whether AICAR can affect adipocyte formation
in vivo, we used the diet induced obesity (DIO) model.
C57BL/6J mice were fed either a standard diet (STD) or a
high-fat diet (DIO) for 6 wk beginning at 10 wk of age,
and treated with AICAR (3 times in a week) at 0.1 mg or
0.5 mg/g body weight for 6 wk. At the beginning of treat-
ment with AICAR, DIO mice weighed 36.1 ± 3.0 g, while
STD mice weighed 28.7 ± 2.5 g. The difference between
the 2 groups was 21% (Fig. 6a). In the DIO group, the
body weight markedly changed following 1 wk treatment,
where the difference between AICAR-treated and vehicle-
treated animals reached -8.7%. The body weight was then
maintained in AICAR-treated mice, while it constantly
increased in the vehicle treated group of DIO mice. At the
end of the experiment (6 weeks), AICAR-treated DIO mice
weighed 15.7% less (-5.7 g) than vehicle-treated DIO
mice. In the STD group, AICAR-treated animal weights
were not significantly changed. However, AICAR at a dose
of 0.1 mg/g bw had no effect on body mass, as compared
to DIO vehicle treated mice. In accordance, DIO vehicle
treated mice had significantly higher epididymal fat con-
tent as compared to STD mice (Fig. 6b). AICAR (0.5 mg/g
bw) treated DIO mice had a significant reduction in epidi-
dymal fat content on par with STD mice, however, AICAR
at the dose of 0.1 g/mg bw had no effect (Fig. 6b). These
results indicate that the higher body weight detected in
DIO vehicle treated mice was at least in part due to an
increase in adipose tissue mass, and that AICAR adminis-
tration (0.5 mg/g bw) significantly normalized the body
weight as well as the fat content (adipose tissue mass)
similar to those in STD vehicle treated mice.
AICAR inhibits adipocyte size without modulating cell 
number or adipogenesis in DIO-treated mice
Since AICAR administration restricted body weight as a
consequence of reduction in fat content of DIO mice, it
was of interest to examine whether AICAR treatment con-
trolled the adipose size or restricted the number of cells.
The size of adipocytes were ascertained by microscopic
analysis and it was observed that DIO vehicle treated mice
had a significant increase in adipocyte size, which was sig-
nificantly restricted in AICAR treated mice at the dose 0.5
mg/g bw while there was no effect at 0.1 mg/g bw (Fig.
7a). On the other hand, no change in the total DNA con-
tent in the adipose tissue of the AICAR treated and vehicle
treated DIO mice was observed, indicating that cell
number was maintained in both cases (Fig. 7b). This sug-
gested that the decrease in epididymal adipose tissue in
AICAR treated DIO mice as compared to DIO vehicle
treated mice was not due to a decrease in cell number.
Effect of AICAR on adipogenic markers in STD and DIO 
treated mice
To examine further whether the decrease in epididymal fat
content was due to an increase in the adipocyte differenti-
ation process, the expression levels for several adipocyte
markers were examined by immunoblot analysis. As
shown in Fig. 8a, the decrease in epididymal fat content
observed in AICAR treated mice (0.5 mg/g bw) was not
reflected in the change in the expression of adipocyte
marker genes such as C/EBPα, C/EBPβ, PPARγ, and
SREBP1. However, we observed a significant increase in
the expression of DGAT and mitochondrial GPAT, two
enzymes involved in the synthesis of triglycerides, by
Effect of AICAR treatment on cell proliferation during the  3T3L1 preadipocyte differentiation induction process Figure 2
Effect of AICAR treatment on cell proliferation dur-
ing the 3T3L1 preadipocyte differentiation induction 
process. 3T3-L1 cells were treated with the indicated con-
centrations of AICAR (from 0.1 to 1.0 mM) during the differ-
entiation induction phase (from day 0 to day2) followed by 
[3H] thymidine uptake to examine cell proliferation. Results 
are the mean ± SD of three determinations. NS not signifi-
cant; *** p < 0.001 as compared with untreated cells.Nutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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Effect of AICAR on the expression of key adipogenic transcription factors during 3T3L1 adipocyte differentiation Figure 3
Effect of AICAR on the expression of key adipogenic transcription factors during 3T3L1 adipocyte differentia-
tion. The differentiating 3T3-L1 cells were treated with different concentrations of AICAR (from 0.1 to 1.0 mM) and proteins 
were isolated at various time periods (from 0 to 9 days). Immunoblot analysis for various key adipogenic transcription factors 
including C/EBPα, C/EBPβ, PPARγ and SREBP1 were examined as described in Materials and Methods (a). The expression lev-
els of PPARγ, SREBP1, C/EBPα, Pref-1, aP2 and adipsin mRNA were estimated by quantitative PCR (qPCR) using their specific 
primers as described in Materials and Methods (b). The relative qPCR values were normalized with respect to 18S rRNA 
expression levels. Values are mean ± S.D. of three determinations. *P < 0.05, *** p < 0.001 as compared with untreated cells. 
NS not significant; *p < 0.05, $ p < 0.001 as compared to 3 days differentiated samples. % p < 0.001 as compared to 6 days dif-
ferentiated samples. @ p < 0.001 as compared to 9 days differentiated samples.Nutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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Adenosine kinase inhibitor (iodotubercidin) reversed the AICAR induced inhibition of 3T3L1 adipocyte differentiation Figure 4
Adenosine kinase inhibitor (iodotubercidin) reversed the AICAR induced inhibition of 3T3L1 adipocyte differ-
entiation. The differentiating 3T3-L1 cells were treated with AICAR (0.5 mM) at various differentiating stages (on 0 day, 3rd 
and 6th day) in the presence or absence of iodotubercidin (0.1 μM). Intracellular lipids were stained with Oil Red O (a). To esti-
mate extent of adipose conversion, 0.2 ml of isopropanol was added to a 12 well plate after 9 days of treatment when AICAR/
iodotubercidin was added at 0 day. The extracted dye was immediately removed by gentle pipetting and its optical density was 
monitored spectrophotometrically at 510 nm (b). Values are mean ± S.D. of three determinations. $ p < 0.001 as compared 
with untreated cells. *** p < 0.001 as compared with differentiated cells. NS not significant; % p < 0.001 as compared with dif-
ferentiated cells and AICAR treated cells, respectively. 3T3-L1 cells were treated with AICAR/iodotubercidin (0.5 mM/0.1 μM) 
during the differentiation induction phase (from day 0 to day2) followed by [3H] thymidine uptake to examine cell proliferation 
(c). Values are mean ± S.D. of three values. *** p < 0.001; NS not significant as compared with untreated cells. * p < 0.05, *** p 
< 0.001 as compared to AICAR treated cells (0.5 and 1.0 mM), respectively. 3T3-L1 cells were differentiated in the presence or 
absence of AICAR/iodotubercidin (0.5 mM/0.1 μM) for 9 days. The protein expression of SREBP1, PPARγ and β actin were 
examined by immunoblot analysis as described previously (d).Nutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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AICAR treatment in STD mice as well as in DIO treated
mice (data not shown).
Biologically active molecules secreted from adipose tissue
called adipokines, have been implicated in the develop-
ment of obesity. The levels of leptin are significantly
increased with the increase in adipose tissue content in
DIO vehicle treated mice. However, AICAR (0.5 mg/g bw)
treatment for 6 weeks brought these back to the normal
levels on par with STD mice (Fig. 9a). In contrast to leptin
levels, adiponectin levels were drastically reduced in DIO
vehicle mice, which also normalized with AICAR treat-
ment (Fig. 9b). Moreover, DIO mice exhibited pro-
nounced dyslipidemia compared to STD mice, as evident
Effect of AICAR on phospho-status of ACC, AMPK during adipocyte differentiation Figure 5
Effect of AICAR on phospho-status of ACC, AMPK during adipocyte differentiation. The differentiating 3T3-L1 
cells were treated with different concentrations of AICAR (from 0.1 to 1.0 mM) and proteins were isolated at various time 
periods (from 0 to 9 days). Immunoblot analysis for p-ACC, p-AMPKα, AMPKα1, AMPKα2 and β actin was examined as 
described in Materials and Methods (a). 3T3L1 cells were differentiated as above in the presence or absence of AICAR (0.5 and 
1.0 mM)/iodotubercidin (0.1 μM) for 9 days. Cells were processed for the immunoblot analysis for p-ACC and β actin (b).Nutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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Effect of AICAR on body weight and epididymal fat content in STD and diet induced obesity mice model Figure 6
Effect of AICAR on body weight and epididymal fat content in STD and diet induced obesity mice model. 
C57B6 mice were kept on standard (STD) or 60% fat diet (DIO) treated with AICAR (0.1 or 0.5 mg/g body weight) or PBS for 
6 weeks intraperitoneally. Body weight of these mice with AICAR was measured periodically (a). At the indicated time periods, 
epididymal fat was isolated and weighed (b). Results are shown as mean ± SD of 10 mice.Nutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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Effect of AICAR on adipocyte size and total DNA content in AICAR treated STD and DIO mice Figure 7
Effect of AICAR on adipocyte size and total DNA content in AICAR treated STD and DIO mice. Paraffin-embed-
ded sections of epididymal white adipose tissue from AICAR treated STD and DIO mice were stained with hematoxylin and 
eosin (ai). Average size of adipocytes measured in 10 different fields is shown at right (aii). ***p < 0.001; NS: not significant as 
compared to STD mice group. $ p < 0.001, as compared to DIO vehicle treated group. NS: not significant as compared to STD 
mice group. White adipose tissue from these treated STD and DIO mice were digested with proteinase K and DNA was 
extracted with phenol:chloroform. DNA content was measured by spectrophotometer (260 nm) (b). NS: not significant as 
compared to STD mice group. $: not significant as compared to DIO vehicle treated group.Nutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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from the elevated levels of triglyceride (TAG), cholesterol
and free fatty acids (FFA), which were significantly
reduced by chronic treatment of AICAR (0.5 mg/g bw)
(Fig. 9c). Furthermore, diet-induced increase in saturated
fatty acids (16:0, 18:0) and decrease in major polyunsatu-
rated fatty acid (18:2) in adipose tissue were also normal-
ized by chronic AICAR treatment (Table 1).
Lipid accumulation and alterations in fatty acid composi-
tion in various tissues as a result of obesity is considered
to be a cause of development of insulin resistance. There-
fore, we examined the glucose tolerance test and insulin
tolerance test in DIO-vehicle and AICAR treated mice after
6 weeks of treatment. As depicted from figure 10a &10b,
DIO-vehicle and AICAR treatment at a dose of 0.1 mg/g
bw showed hyperglycemia and hyperisulinemia, how-
ever, AICAR treated DIO mice at the dose of 0.5 mg/g bw
completely ameliorated hyperglycemia and hyperisuline-
mia induced by the high fat diet. We also determined the
TGA and FFA content in liver of DIO vehicle and AICAR
treated DIO (0.5 mg/g bw) mice and observed that DIO
vehicle treated mice exhibited a significant increase in
TGA and FFA levels, which were significantly inhibited by
AICAR treatment (data not shown). This indicates that the
differences in glucose tolerance and insulin sensitivity
observed between DIO and AICAR treated DIO (0.5 mg/g
bw) mice is due to a decrease in lipid storage in adipose
tissue and liver in AICAR treated DIO mice (0.5 mg/g bw),
which probably prevented the further impairment of glu-
cose homeostasis. Since lipid accumulation in tissues
other than adipose tissue, such as liver, is considered to be
a cause of the development of insulin resistance associ-
ated with obesity.
AICAR activates AMPK in adipose tissue
We examined further the possibility of activation of AMPK
in adipose tissue by chronic treatment with AICAR. For
this, we examined the phospho-status of AMPKα and ACC
as well as the total level of AMPKα1 in adipose tissue after
6 weeks of AICAR treatment in STD and DIO mice. AICAR
treatment at both doses induced the phosphorylation of
AMPKα as compared to STD and DIO vehicle treated mice
(Fig. 11a). However, the phospho-status of ACC was only
increased in the AICAR treated STD mice, and did not
show any change in DIO-vehicle treated, as well as in
AICAR treated DIO mice. No change was observed in the
total level of AMPKα1 in any treatment in STD and DIO
mice. However, a significant increase in the enzymatic
activity of AMPKα1 was observed in AICAR treated STD,
in DIO-vehicle treated and AICAR treated (0.1 mg/g bw)
adipose tissue (Figure 11b). AICAR treated adipose tissue
at a dose of 0.5 mg/g bw also showed a significant increase
in AMPKα1 activity but the increase in its activity was not
significantly higher than that observed in other group.
AICAR induced expression of PGC1α
Proliferator-activated receptor γ coactivator 1α (PGC-1α)
is a coactivator of nuclear receptors and other transcrip-
tion factors [35]. PGC-1α controls mitochondrial biogen-
esis and oxidative metabolism in many tissues, including
brown adipose tissue, skeletal muscle, heart, and liver [36-
39]. We examined the effect of AICAR on DIO vehicle
treated mice and observed that AICAR treatment of STD
mice significantly induced protein expression as com-
pared to that in untreated STD mice (Fig. 12a). The expres-
sion of PGC1α was found to be significantly down in
adipose tissue in DIO vehicle and AICAR (0.1 mg/g bw)
treated mice, however AICAR at the dose of 0.5 mg/g bw
significantly reversed the protein expression of PGC1α
induced in DIO as documented by immunoblot and its
densitometry analysis (Figure 12ai &12aii). These obser-
vations were further supported by quantitative PCR for
PGC1α in adipose tissue from AICAR treated STD and
DIO mice (Fig. 12b). To examine the effect of AICAR on
the expression of PGC1α, 3T3L1 cells were treated with
increasing concentrations of AICAR (0.1–1.0 mM) under
differentiating condition and the expression of PGC1 α
was examined at 3, 6 and 9 days using immunoblot anal-
ysis. As depicted from figure 12c, treatment of AICAR
induced the protein expression of PGC1α at day 3 in dose
dependent manner, however, higher concentration of
Effect of AICAR on adipocyte protein marker expression in  DIO treated mice after 6 weeks of treatment Figure 8
Effect of AICAR on adipocyte protein marker 
expression in DIO treated mice after 6 weeks of 
treatment. Total protein epididymal fat content from 6 
weeks AICAR treated STD and DIO treated mice was iso-
lated. The expression for various key adipogenic transcrip-
tion factors including C/EBPα, C/EBPβ, PPARγ and SREBP1 
was examined by immunoblot analysis as described in Materi-
als and Methods.Nutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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AICAR (0.5 and 1 mM) induced the highest expression at
day 3 after that there was a decrease in its expression.
Discussion
Obesity is a metabolic disorder, resulting from an imbal-
ance between metabolizable energy intake and energy
expenditure [40]. The increase in obesity is particularly
marked in children, and not just confined to the Western
world [41]. In the present study, we examined the effect of
AICAR, a pharmacological activator of AMPK, on in vitro
adipocyte differentiation of 3T3L1 and in vivo diet
induced obesity mouse model (DIO). We observed that
Effect of AICAR on metabolic alterations in AICAR treated STD and DIO treated mice Figure 9
Effect of AICAR on metabolic alterations in AICAR treated STD and DIO treated mice. Blood was withdrawn 
from AICAR treated STD and DIO treated mice after 6 weeks of treatment and serum was isolated and the levels of leptin and 
adiponectin were examined by the respective ELISA kits as described in Material and Methods (a). Values are mean ± S.D. of 
eight values. * p < 0.05; ** p < 0.01; NS: not significant as compared to STD mice group. $ p < 0.05, as compared to DIO vehi-
cle treated group. NS: not significant as compared to STD mice group. The lipid profile (TAG, cholesterol and FFA) was exam-
ined as described in Material and Methods (b). Values are mean ± SD of 4 different sera. For TAG, ** p < 0.01; NS: not 
significant as compared to STD mice group. $ p < 0.001, as compared to DIO vehicle treated group. NS: not significant as com-
pared to STD mice group. For Cholesterol, *** p < 0.001; * p < 0.05; NS: not significant as compared to STD mice group. $ p 
< 0.001, as compared to DIO vehicle treated group. NS: not significant as compared to STD mice group. For FFA, *** p < 
0.001; NS: not significant as compared to STD mice group. $ p < 0.001, as compared to DIO vehicle treated group. NS: not sig-
nificant as compared to STD mice group.Nutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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AICAR inhibited adipocyte differentiation in 3T3L1 cells
via downregulation of important transcription factors
such as C/EBPα, PPARγ and SREBP1, which strictly con-
trol adipocyte differention.
The CCAAT element-binding proteins (C/EBP) β and δ
and sterol response element-binding protein 1 (ADD1/
SREBP1) are active during the early stages of the differen-
tiation process and induce the expression and/or activity
of the peroxisome proliferator-activated receptor γ
(PPARγ), a pivotal coordinator of adipocyte differentia-
tion [42]. Activated PPARγ induces exit from the cell cycle,
and in cooperation with C/EBPα, stimulates the expres-
sion of many metabolic genes [42]. Our observation is in
accordance with a previous report where AICAR was
shown to inhibit C/EBPα and PPARγ due to the inhibition
of early clonal expansion of pre-adipocytes [43]. Our data
shows that inhibition of adipogenic differentiation in
3T3L1 is not just confined to early clonal expansion, since
addition of AICAR either at early differentiation stage (day
3) or at late differentiation stage (day 6), significantly
blocked 3T3L1 differentiation. We speculate this effect is
due to the repression of PPARγ dependent transcription
by AMPK activation via phosphorylation of p300 at serine
89 [44,45], however, it remains to be established in adi-
pogenic differentiation.
During 3T3L1 differentiation, there was an increase in
ACC and AMPK phosphorylation at days 3, 6 and 9, sug-
gesting the activation of AMPK. But the role of activation
AMPK in the regulation of differentiation remains to be
explored. Incubation of 3T3L1 cells, undergoing differen-
tiation, with AICAR at the concentration of 0.1 and 0.25
mM, induced the phosphorylation of ACC and AMPK at
day 6 and 9. However, at the higher concentration (0.5
and 1 mM) it does not induce ACC and AMPK phosphor-
ylation compared to untreated differentiated cells at day
9. Moreover, adenosine kinase inhibitor (iodotubercidin)
completely reversed AICAR mediated inhibition of adi-
pocyte differentiation, expression of SREBP-1 and PPARγ.
Increase in phosphorylation of ACC and AMPKα during
adipocyte differentiation in time dependent manner indi-
cating the possible activation/involvement of AMPK dur-
ing adipocyte differentiation. Moreover, adenosine kinase
inhibitor also reversed the AICAR-mediated downregula-
tion of phosphorylation of ACC at day 9, further suggest-
ing that AICAR mediated effect may not be due to AMPK
activation and requires more in-depth studies in this proc-
ess.
To investigate further the effect of AICAR on adipocyte
content in vivo, we employed the diet induced obesity
model where we administered two doses of AICAR (0.1
and 0.5 mg/g kb) for 6 weeks. The lower dose of AICAR
(0.1 mg/g) did not modulate either the body weight or
total epididymal fat content in DIO treated mice. How-
ever at 0.5 mg/g bw dose, AICAR was found to be very
effective in maintaining body weight and epididymal fat
content, restoring levels of adipokines and significantly
improving glucose tolerance and insulin sensitivity, as
compared to DIO vehicle treated mice. Other reports have
demonstrated chronic administration of AICAR to dimin-
ish the mass of fat pads significantly while having no
effect on body weight in treated rats [24,46]. Another
report [47] showed that in fatty rats (fa/fa) treated with
AICAR (0.5 mg/g) daily resulted in a modest decrease in
intra-abdominal adiposity (15%), as compared with pair-
fed animals and improved metabolic disturbances. All
these reports suggest that AICAR administration leads to
decrease in food intake [24,46,47], however, we did not
observe any change in food intake at any dose of AICAR
treatment (Data not shown). AICAR treatment (0.5 mg/
kg) also restored the levels of adipokines (adiponectin
and leptin) in DIO mice as compared to vehicle treated
mice. The main sources of these adipokines, the adipose
tissue, are well known to activate AMPK and it will be
interesting to understand how AICAR regulates the pro-
duction of these adipokines in DIO treated mice. In con-
trast to our in vivo observation, AMPK activators have been
shown to inhibit the production of adiponectin in 3T3L1
adipocytes [48].
AICAR administration induced the activation of AMPKα1
enzymatic activity as well as phosphorylation of AMPKα
Table 1: Effects of AICAR treatment on fatty acid composition (weight %) of adipose tissue in normal and diet-induced obese mice
Group/Fatty acid 14:0 16:0 18:0 18:2
STD 0.89 ± 0.02 18.6 ± 0.1 1.9 ± 0.06 27.1 ± 0.35
STD+A500 0.9 ± 0.01 22.2 ± 0.21 3.0 ± 0.15 28.9 ± 0.81
DIO 1.3 ± 0.2 26.6 ± 0.21* 3.6 ± 0.15* 15.9 ± 1.3*
DIO+A100 0.95 ± 0.03 24.3 ± 0.38 4.4 ± 0.06 28.7 ± 0.86
DIO+A500 1.1 ± 0.1 23.3 ± 0.26** 2.5 ± 0.21** 22.2 ± 0.7**
Adipose tissue was isolated and prepared as described in Methods. The lipids were extracted in chloroform-methanol using Folch partition. Fatty 
acid methyl ester was prepared with methanolic-HCl, purified by TLC and analyzed by GC as described in our earlier publication [29]. Fatty acids 
showing significant alteration in composition are included and their peaks were identified using known standards. Values are expressed as mean ± 
SD for 3 separate sets of experiments. *p < 0.001 vs STD, **p < 0.001 vs DIO.Nutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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Effect of AICAR on glucose and insulin tolerance tests in AICAR treated STD and DIO treated mice Figure 10
Effect of AICAR on glucose and insulin tolerance tests in AICAR treated STD and DIO treated mice. For glu-
cose tolerance test, overnight-fasted mice from all groups were given an intraperitoneal injection of glucose (2 mg/g body wt). 
Blood samples were withdrawn from the tail and analyzed for glucose levels at the indicated time points (15 to 120 min) (a). 
For insulin tolerance test, insulin (0.5 units/kg body wt) was intraperitoneal injected after fasting for 12 h, and glucose levels 
were monitored at the indicated time points (15 to 120 min)(b). Results are the means ± SD from four animals.Nutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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Effect of AICAR on phospho-status of ACC, AMPK and AMPK enzymatic activity in AICAR treated STD and DIO treated mice Figure 11
Effect of AICAR on phospho-status of ACC, AMPK and AMPK enzymatic activity in AICAR treated STD and 
DIO treated mice. Total protein from epididymal fat content from 6 weeks AICAR treated STD and DIO treated mice was 
isolated. Immunoblot analysis for p-ACC, p-AMPKα, AMPKα1 and β actin was examined as described in Materials and Meth-
ods (a). The enzymatic activity of AMPKα1 was examined by immunoprecipitating using anti-AMPKα1 followed by assessing its 
activity using SAMS peptide as described in Material and methods (b). *** p < 0.001; ** p < 0.01 as compared to STD mice 
group. $ p < 0.05, as compared to DIO vehicle treated group.Nutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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in STD and DIO treated adipose tissue. However, adipose
tissue from DIO vehicle treated mice showed significant
activation of AMPKα1 as compared to adipose tissues
from STD vehicle treated mice. This is in contrast with
another report, where they did not observe any changes in
the AMPK activity in adipose tissue treated with AICAR,
AICAR induced the expression of PGC1α in white adipose tissue in DIO treated mice Figure 12
AICAR induced the expression of PGC1α in white adipose tissue in DIO treated mice. Total protein from epididy-
mal fat content from 6 weeks AICAR treated STD and DIO treated mice was isolated and immunoblot analysis for PGC1α was 
examined (a i). Densitometry values for PGC1α were normalized with β actin and plotted as a bar graph (a ii). The expression 
of PGC1α was quantified by qPCR (b). The relative qPCR values were normalized with respect to the 18S rRNA expression 
level. Values are mean ± S.D. for three mice. *** p < 0.001; ** p < 0.01 as compared to STD mice group. $ p < 0.001, as com-
pared to DIO vehicle treated group. The differentiating 3T3-L1 cells were treated with different concentrations of AICAR 
(from 0.1 to 1.0 mM) and proteins were isolated at various time periods (from 0 to 9 days). Immunoblot analysis for PGC1α 
and β actin was examined as described in Materials and Methods (c).Nutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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even though the accumulation of ZMP was observed in
adipose tissue of these animals [47]. The molecular mech-
anisms underlying the role of AMPK in adipose tissue are
not fully known. Adipose tissue from 0.1 mg/kb AICAR
treated DIO mice also exhibited increase AMPKα1 activ-
ity. However, there is no reduction in metabolic alteration
compared with untreated DIO mice further questioning
the involvement of AMPK in the regulation of metabolic
alteration.
Increase in adipose tissue mass may be due to an increase
in the number of adipose cells, or an increase in triglycer-
ide storage in the preexisting adipocytes, or a combination
of both processes. Though AICAR administration signifi-
cantly decreased epididymal fat content, no change was
observed in the expression of key adipogenic factors such
as C/EBPα, PPARγ, SREBP-1 with significant induction of
C/EBPβ in AICAR treated STD and DIO treated animals.
Untreated STD animals had significant expression of these
adipogenic factors suggesting that STD mice already had
fully differentiated adipocytes, which suggests that the
reduction in epididymal fat content observed in AICAR
treated DIO mice is not due to blockage of preadipocyte
differentiation into adipocytes as observed in vitro 3T3L1
adipocyte differentiating model. We observed the reduc-
tion of C/EBPβ levels in DIO vehicle treated mice, which
is restored by AICAR treatment. The expression of C/EBPβ
decreased as adipocyte differentiation progressed. Resto-
ration of C/EBPβ protein by AICAR treatment can be due
to the suppression of cytoplasmic HuR protein [49],
which may result in the accumulation of C/EBPβ protein
since C/EBPβ message is a ligand for HuR [50] and regu-
lates the early event of adipogenesis.
Another possibility for the reduction of epididymal fat
content and the size of adipocytes observed in AICAR
treated DIO mice may be due to cellular hypotrophy
which results in decreased triglyceride accumulation inthe
pre-existing adipocytes, rather than an increase in cell
number or differentiation. In AICAR treated DIO mice,
the decreasedtriglyceride accumulation in adipose tissue
could be due to decreased triglyceride synthesis or
increased lipolysis. Triglyceride synthesis is regulated by
mitochondrial GPAT and DGAT, two enzymes involved in
the esterification of fatty acids to triglycerides. Mitochon-
drial GPAT have been shown to be the substrates for
AMPK, resulting in the inhibition of enzymatic activity
[51]. According to our observation AICAR treatment (0.5
mg/g bw) significantly induced the expression of both
GPAT and DGAT in adipose tissue of STD and DIO treated
animals. The decrease in the content of adipose tissue in
AICAR (0.5 mg/g bw) treated DIO and increase in the
expression of these enzymes cannot be explained at
present. In terms of regulation of lipolysis in rodent adi-
pocytes, the role of AMPK remains controversial [52,53].
Recently, using pharmacological activators, adenoviruses
expressing either dominant negative or constitutively
active forms of AMPK and AMPKα1 knockout mice, have
clearly demonstrated that AMPK activation has an anti-
lipolytic effect in rodent adipocytes [54]. At present, we do
not have any explanation how AICAR reduced the epidi-
dymal fat content in DIO treated mice when the expres-
sion of GPAT and DGAT is significantly increased and
AMPK has been shown to be anti-lipolytic in adipocytes
[54].
Decrease in adiposity caused by AICAR in DIO treated
mice is attributable, at least in part, to increase in energy
expenditure. AICAR has been shown to increase expres-
sion of the uncoupling proteins UCP3 [55,56] and the
transcription factor PGC1α [57] in rat skeletal muscle.
Peroxisomal proliferator activator receptor (PPAR)
gamma co-activator 1alpha (PGC1α) is a transcriptional
coactivator that has recently been highlighted as an
important regulator of gluconeogenesis, fatty-acid oxida-
tion and adaptive thermogenesis [37]. Moreover, the
expression of PGC1α was found to be reduced in skeletal
muscle of prediabetic and diabetic subjects [58] and in
adipose tissue of morbidly obese people [59]. We also
observed the reduced protein and mRNA expression of
PGC1α in adipose tissue of DIO vehicle treated mice,
which was significantly induced by AICAR treatment not
only in DIO treated mice but also in STD treated mice.
Similar observation was found in 3T3L1 cells when cells
were treated with different concentration of AICAR, the
expression of PGC1α increased in dose dependent man-
ner at day 3. Why treatment of of higher concentration of
AICAR (0.5 and 1 mM) abolished the expression of
PGC1α at days (6 and 9), which was induced at day 3, can
not be explained at present? However, AICAR mediated
reduction in adipose tissue of DIO treated mice may be
due to the expression of PGC1α, which plays an impor-
tant role in adaptive thermogenesis by regulating the
expression of UCP-1, a key molecule that uncouples ATP
synthesis from mitochondrial respiration, resulting in
heat production [35]. Recent two studies also supported
our observation that AICAR treatment induces the PGC1α
expression [60,61]. Moreover, AMPK has also been shown
to induce mitochondrial biogenesis [60] and up-regulate
nuclear respiratory factor-1 (NRF-1) whose expression is
controlled by PGC1α [62].
Conclusion
Our study demonstrates that AICAR treatment signifi-
cantly attenuates adipoctye differentiation in vitro. How-
ever, its administration restricted the body weight,
epididymal fat content and normalized metabolic altera-
tion mediated by diet induced obesity in mice. Increase in
phosphorylation of ACC and AMPKα during adipocyte
differentiation and AMPK activity in epididymal adiposeNutrition & Metabolism 2006, 3:31 http://www.nutritionandmetabolism.com/content/3/1/31
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tissue in DIO mice raises doubts about the involvement of
AMPK in this process.
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